Limitations, agreements, and source contact

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer · Source last updated 2021-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

clinicaltrials@pumabiotechnology.com

organization

Puma Biotechnology, Inc.

phone

+1 (424) 248-6500

title

Senior Director, Clinical Operations

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice